Medicare Expands Coverage for iMDx Transplant Test, Boosting Commercial Outlook
IMDX sits 99% above its 52-week low of $2.33 on light trading volume (0.3× avg).
Summary
Medicare issued a final LCD that significantly expands coverage for dd-cfDNA transplant monitoring, directly benefiting iMDx's GraftAssure portfolio. The policy increases surveillance testing frequency across kidney and heart transplants—doubling allowed tests in years 2-3 and removing the cap beyond year 3—and cites iMDx-affiliated research. This strengthens the reimbursement framework ahead of the company's planned kit-based commercial launch, with a $2,753 per-test Medicare rate already established for its lab-developed test. The decision follows positive clinical data published in June and comes as iMDx awaits FDA marketing authorization for GraftAssureDx, which would allow transplant centers to run the test in-house and bill Medicare directly. The expanded coverage directly enlarges the addressable market and improves the economic case for adoption.
At the time of this announcement, IMDX was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.5M. The 52-week trading range was $2.33 to $8.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.